Piper Sandler initiated coverage of Nektar (NKTR) with an Overweight rating and $7 price target The analyst believes Nektar’s lead asset rezpegaldesleukin has a differentiated IL-2Ralpha mechanaism of action that selectively stimulates tregs. The firm has a high probability of success for rezpegaldesleukin, saying the Phase 1b atopic dermatitis trial demonstrated robust efficacy and safety and validated the utility of targeted treg stimulation.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter